APLIF and APLI Related Headlines
Go Back- Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
- Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
- Appili Therapeutics to Exhibit at World Vaccine Congress Washington
- Appili Therapeutics closes C$100,000 private placement second tranche
- Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
- Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
- Appili Therapeutics raises C$177,500 in first tranche of private placement
- Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
- Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
- Appili Therapeutics announces C$750,000 private placement
- Appili Therapeutics Announces Proposed Non-Brokered Private Placement
- Appili Therapeutics to Attend BARDA Innovation Symposium 2025
APLIF and APLI Related Press Releases
Go Back- Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
- Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
- Appili Therapeutics to Exhibit at World Vaccine Congress Washington
- Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
- Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
- Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
- Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
- Appili Therapeutics Announces Proposed Non-Brokered Private Placement
- Appili Therapeutics to Attend BARDA Innovation Symposium 2025
